Cognitive-enhancing activity of thymol and carvacrol in two rat models of dementia

Behavioural Pharmacology

Volumn 23, Issue 3, 2012, Pages 241-249

  Azizi, Zahra ^a   Ebrahimi, Shima ^a   Saadatfar, Elshaan ^a   Kamalinejad, Mohammad ^b   Majlessi, Nahid ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alzheimer's disease; Amyloid b; Carvacrol; Morris water maze; Scopolamine; Thymol

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CARVACROL; SCOPOLAMINE; THYMOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLINESTERASE INHIBITION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ESCAPE BEHAVIOR; LATENT PERIOD; LD 50; LEARNING; MALE; MAZE TEST; MOTIVATION; NONHUMAN; RAT; SENSORIMOTOR FUNCTION;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; CHOLINESTERASE INHIBITORS; COGNITION; DEMENTIA; DISEASE MODELS, ANIMAL; MALE; MICE; MONOTERPENES; RATS; RATS, WISTAR; SCOPOLAMINE HYDROBROMIDE; THYMOL;

EID: 84860704803     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283534301     Document Type: Article

References (66)

1. Aeschbach R, Lö liger J, Scott BC, Murcia A, Butler J, Halliwell B, Aruoma OI (1994). Antioxidant actions of thymol, carvacrol, 6-gingerol, zingerone and hydroxytyrosol. Food Chem Toxicol 32:31-36.
2. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. (2000). Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421.
3. Andersen A (2006). Final report on the safety assessment of sodium p-chlorom-cresol, p-chloro-m-cresol, chlorothymol, mixed cresols, m-cresol, o-cresol, p-cresol, isopropyl cresols, thymol, o-cymen-5-ol, and carvacrol. Int J Toxicol 25 (Suppl 1):29-127.
4. Anekonda TS, Reddy PH (2005). Can herbs provide a new generation of drugs for treating Alzheimer's disease? Brain Res Brain Res Rev 50:361-376.
5. Aristatile B, Al-Numair KS, Veeramani C, Pugalendi KV (2009). Antihyperlipidemic effect of carvacrol on D-galactosamine-induced hepatotoxic rats. J Basic Clin Physiol Pharmacol 20:15-27.
6. Aydin Y, Kutlay O, Ari S, Duman S, Uzuner K, Aydin S (2007). Hypotensive effects of carvacrol on the blood pressure of normotensive rats. Planta Med 73:1365-1371.
7. Bartus RT, Dean RL, Beer B, Lippa AS (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-417.
8. Basch E, Ulbricht C, Hammerness P, Bevins A, Sollars D (2004). Thyme (Thymus vulgaris L.), thymol. J Herb Pharmacother 4:49-67.
9. Baser KH (2008). Biological and pharmacological activities of carvacrol and carvacrol bearing essential oils. Curr Pharm Des 14:3106-3119.
10. Bassil N, Grossberg GT (2009). Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs 23:293-307.
11. Bastianetto S, Quirion R (2002). Natural extracts as possible protective agents of brain aging. Neurobiol Aging 23:891-897.
12. Bennett S, Grant MM, Aldred S (2009). Oxidative stress in vascular dementia and Alzheimer's disease: a common pathology. J Alzheimers Dis 17:245-257.
13. Bharadwaj PR, Dubey AK, Masters CL, Martins RN, Macreadie IG (2009). Abeta aggregation and possible implications in Alzheimer's disease pathogenesis. J Cell Mol Med 13:412-421.
14. Bhattaram VA, Graefe U, Kohlert C, Veit M, Derendorf H (2002). Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine 9 (Suppl 3):1-33.
15. Braga PC, Dal Sasso M, Culici M, Bianchi T, Bordoni L, Marabini L (2006). Antiinflammatory activity of thymol: inhibitory effect on the release of human neutrophil elastase. Pharmacology 77:130-136.
16. Brodaty H, Breteler MM, Dekosky ST, Dorenlot P, Fratiglioni L, Hock C, et al. (2011). The world of dementia beyond 2020. J Am Geriatr Soc 59: 923-927.
17. De Vincenzi M, Stammati A, De Vincenzi A, Silano M (2004). Constituents of aromatic plants: carvacrol. Fitoterapia 75:801-804.
18. Didry N, Dubreuil L, Pinkas M (1994). Activity of thymol, carvacrol, cinnamaldehyde and eugenol on oral bacteria. Pharm Acta Helv 69:25-28.
19. Drachman DA, Leavitt J (1974). Human memory and the cholinergic system. A relationship to aging? Arch Neurol 30:113-121.
20. Duyckaerts C, Delatour B, Potier MC (2009). Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118:5-36.
21. Ebert U, Kirch W (1998). Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest 28: 944-949.
22. Farlow MR, Miller ML, Pejovic V (2008). Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 25:408-422.
23. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010). Mechanisms underlying inflammation in neurodegeneration. Cell 140:918-934.
24. Howes MJ, Perry NS, Houghton PJ (2003). Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res 17:1-18.
25. Ipek E, Tü ylü BA, Zeytinog? lu H (2003). Effects of carvacrol on sister chromatid exchanges in human lymphocyte cultures. Cytotechnology 43: 145-148.
26. Jukic M, Politeo O, Maksimovic M, Milos M, Milos M (2007). In vitro acetylcholinesterase inhibitory properties of thymol, carvacrol and their derivatives thymoquinone and thymohydroquinone. Phytother Res 21:259-261.
27. Kaminsky YG, Marlatt MW, Smith MA, Kosenko EA (2010). Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35). Exp Neurol 221:26-37.
28. Kim J, Lee HJ, Lee KW (2010). Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J Neurochem 112:1415-1430.
29. Kordali S, Cakir A, Ozer H, Cakmakci R, Kesdek M, Mete E (2008). Antifungal, phytotoxic and insecticidal properties of essential oil isolated from Turkish Origanum acutidens and its three components, carvacrol, thymol and p-cymene. Bioresour Technol 99:8788-8795.
30. Lambert RJ, Skandamis PN, Coote PJ, Nychas GJ (2001). A study of the minimum inhibitory concentration and mode of action of oregano essential oil, thymol and carvacrol. J Appl Microbiol 91:453-462.
31. Landa P, Kokoska L, Pribylova M, Vanek T, Marsik P (2009). In vitro antiinflammatory activity of carvacrol: inhibitory effect on COX-2 catalyzed prostaglandin E(2) biosynthesis. Arch Pharm Res 32:75-78.
32. Lleó A, Greenberg SM, Growdon JH (2006). Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 57:513-533.
33. Lorke D (1983). A new approach to practical acute toxicity testing. Arch Toxicol 54:275-287.
34. Majlessi N, Choopani S, Bozorgmehr T, Azizi Z (2008). Involvement of hippocampal nitric oxide in spatial learning in the rat. Neurobiol Learn Mem 90:413-419.
35. Majlessi N, Choopani S, Kamalinejad M, Azizi Z (2011). Amelioration of amyloid b-induced cognitive deficits by Zataria multiflora Boiss. Essential oil in a rat model of Alzheimer's disease. CNS Neurosci Ther. doi:10.1111/j.1755- 5949.2011.00237. [Epub ahead of print].
36. May BH, Lit M, Xue CC, Yang AW, Zhang AL, Owens MD, et al. (2009). Herbal medicine for dementia: a systematic review. Phytother Res 23:447-459.
37. McNaull BB, Todd S, McGuinness B, Passmore AP (2010). Inflammation and anti-inflammatory strategies for Alzheimer's disease-a mini-review. Gerontology 56:3-14.
38. Melo FH, Venâncio ET, de Sousa DP, de França Fonteles MM, de Vasconcelos SM, Viana GS, de Sousa FC (2010). Anxiolytic-like effect of carvacrol (5-isopropyl-2-methylphenol) in mice: involvement with GABAergic transmission. Fundam Clin Pharmacol 24:437-443.
39. Melo FH, Moura BA, de Sousa DP, de Vasconcelos SM, Macedo DS, Fonteles MM, et al. (2011). Antidepressant-like effect of carvacrol (5-isopropyl-2- methylphenol) in mice: involvement of dopaminergic system. Fundam Clin Pharmacol 25:362-367.
40. Mimica N, Presecki P (2009). Side effects of approved antidementives. Psychiatr Danub 21:108-113.
41. Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR (2009). An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J Alzheimers Dis 16:741-761.
42. Mukherjee PK, Kumar V, Mal M, Houghton PJ (2007). Acetylcholinesterase inhibitors from plants. Phytomedicine 14:289-300.
43. Neugroschl J, Sano M (2009). An update on treatment and prevention strategies for Alzheimer's disease. Curr Neurol Neurosci Rep 9:368-376.
44. Orhan I, Kartal M, Kan Y, Sener B (2008). Activity of essential oils and individual components against acetyl-and butyrylcholinesterase. Z Naturforsch C 63:547-553.
45. Panza F, Solfrizzi V, Frisardi V, Capurso C, D'Introno A, Colacicco AM, et al. (2009). Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 26:537-555.
46. Paxinos G, Watson C (1986). The rat brain in stereotaxic coordinates. 2nd ed. Orlando: Academic Press.
47. Peixoto-Neves D, Silva-Alves KS, Gomes MD, Lima FC, Lahlou S, Magalhães PJ, et al. (2010). Vasorelaxant effects of the monoterpenic phenol isomers, carvacrol and thymol, on rat isolated aorta. Fundam Clin Pharmacol 24:341-350.
48. Pendry B, Busia K, Bell CM (2005). Phytochemical evaluation of selected antioxidant-containing medicinal plants for use in the preparation of a herbal formula-a preliminary study. Chem Biodivers 2:917-922.
49. Qiu C, Kivipelto M, von Strauss E (2009). Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11:111-128.
50. Ray B, Lahiri DK (2009). Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol 9:434-444.
51. Reddy VP, Zhu X, Perry G, Smith MA (2009). Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis 16:763-774.
52. Reitz C, Brayne C, Mayeux R (2011). Epidemiology of Alzheimer disease. Nat Rev Neurol 7:137-152.
53. Rodrigue KM, Kennedy KM, Park DC (2009). Beta-amyloid deposition and the aging brain. Neuropsychol Rev 19:436-450.
54. Savelev SU, Okello EJ, Perry EK (2004). Butyryl-and acetyl-cholinesterase inhibitory activities in essential oils of Salvia species and their constituents. Phytother Res 18:315-324.
55. Shi Q, Gibson GE (2007). Oxidative stress and transcriptional regulation in Alzheimer disease. Alzheimer Dis Assoc Disord 21:276-291.
56. Slamenová D, Horváthová E, Sramková M, Marsá lková L (2007). DNA-protective effects of two components of essential plant oils carvacrol and thymol on mammalian cells cultured in vitro. Neoplasma 54:108-112.
57. Spencer B, Rockenstein E, Crews L, Marr R, Masliah E (2007). Novel strategies for Alzheimer's disease treatment. Expert Opin Biol Ther 7:1853-1867.
58. Stammati A, Bonsi P, Zucco F, Moezelaar R, Alakomi HL, von Wright A (1999). Toxicity of selected plant volatiles in microbial and mammalian short-term assays. Food Chem Toxicol 37:813-823.
59. Steele M, Stuchbury G, Münch G (2007). The molecular basis of the prevention of Alzheimer's disease through healthy nutrition. Exp Gerontol 42:28-36.
60. Stéphan A, Phillips AG (2005). A case for a non-transgenic animal model of Alzheimer's disease. Genes Brain Behav 4:157-172.
61. Thathiah A, De Strooper B (2009). G protein-coupled receptors, cholinergic dysfunction, and Abeta toxicity in Alzheimer's disease. Sci Signal 2:re8.
62. Van Dam D, De Deyn PP (2006). Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 5:956-970.
63. Van Den Broucke CO, Lemli JA (1982). Antispasmodic activity of Origanum compactum. Planta Med 45:188-190.
64. Weingartner H (1985). Models of memory dysfunctions. Ann NY Acad Sci 444:359-369.
65. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR (1981). Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10:122-126.
66. Yamin G (2009). NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus. J Neurosci Res 87:1729-1736.